The Prognostic Impact of Radioiodine Therapy in Patients with Papillary Thyroid Cancer

Abstract

Radioiodine (RAI) therapy after surgery, is an important component for the treatment of patients with papillary thyroid cancer (PTC), the most common thyroid cancer. In this study we sought to evaluate the cancer-specific survival (CSS) impact of RAI in specific thyroid cancer subgroups. The Surveillance, Epidemiology, and End Results (SEER) database were used to identify patients with PTC who underwent surgery between 2000 and 2019. Patients not treated with RAI were compared to those treated with RAI using propensity score matching (PSM) on the basis of identical inclusion criteria. A total of 106 333 patients were identified from the SEER database. RAI therapy was associated with improved CSS in the matched cohort (HR: 0.83; 95% CI: 0.72–0.96, p=0.01) but not in the unmatched data set (HR: 1.46; 95% CI: 1.30–1.64, p<0.001) among all PTC patients regardless of disease stage. Detailed analyses, however, showed that only patients with high-risk disease (pT3N1, pT4N1) experienced the greatest benefit in CSS. In the lower disease stages, no significant differences were recognized in the group of PTC patients with or without RAI therapy. One exception: in the group of PTC patients in stage pT1bN0, a significant difference was seen towards RAI. This is, however, most likely due to the large number of patients investigated. In summary, RAI therapy should not be used in low-risk PTC patients and might be used to some extent in intermediate-risk PTC patients. The histological suptype of the tumor needs to be considered in this context.

Keywords

papillary thyroid cancer - radioiodine therapy - cancer-specific mortality - SEER database

Publikationsverlauf

Eingereicht: 20. August 2024

Angenommen nach Revision: 22. September 2024

Artikel online veröffentlicht:
07. November 2024

• References

• 1 Vaccarella S, Franceschi S, Bray F. et al. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med 2016; 375: 614-617
• 2 Sherman SI. Thyroid carcinoma. Lancet 2003; 361: 501-511
• 3 Subramanian S, Goldstein DP, Parlea L. et al. Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid 2007; 17: 1277-1288
• 4 Krieg A, Krieg S, Al Natour OMS. et al. Risk of lymphoma and leukemia in thyroid cancer patients: a retrospective cohort study in Germany. Horm Metab Res 2024; 56: 559-565
• 5 Sawka AM, Thabane L, Parlea L. et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 2009; 19: 451-457
• 6 Haugen BR, Alexander EK, Bible KC. et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26: 1-133
• 7 Jonklaas J, Sarlis NJ, Litofsky D. et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006; 16: 1229-1242
• 8 Pacini F, Fuhrer D, Elisei R. et al. 2022 ETA consensus statement: what are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?. Eur Thyroid J 2022; 11: e210046
• 9 Schmidt M, Bartenstein P, Bucerius J. et al. Individualized treatment of differentiated thyroid cancer: the value of surgery in combination with radioiodine imaging and therapy – a German position paper from surgery and nuclear medicine. Nuklearmedizin 2022; 61: 87-96
• 10 Surveillance, Epidemiology, and End Results (SEER) Program www.seer.cancer.gov SEER*Stat Database: Incidence – SEER Research Plus Data, 17 Registries, Nov 2021 Sub (2000–2019) – Linked to County Attributes – Total U.S., 1969–2019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2021, based on November 2020 submission
• 11 Doll KM, Rademaker A, Sosa JA. Practical guide to surgical data sets: surveillance, epidemiology, and end results (SEER) database. JAMA Surg 2018; 153: 588-589
• 12 Zhang Z. Multiple imputation with multivariate imputation by chained equation (MICE) package. Ann Transl Med 2016; 4: 30
• 13 Wickham H, Bryy J. Read Excel Files, R Package Version 1.4.2. 2022. [(accessed on 14 November 2022)]. Available online https://CRAN.R-project.org/package=readxl 2022
• 14 Van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J Stat. Softw. 2011 45. 1-67
• 15 Ho D, Imai K, King G. et al. MatchIt: nonparametric preprocessing for parametric causal iunference. J Statist Software 2011; 42: 1-28
• 16 Greifer N. Cobalt: covariate balance tables and plots. R package version 4.5.5.9000 https://github.com/ngreifer/cobalt 2024
• 17 Survival analysis. R package version 3.3-1 https://cran.r-project.org/web/packages/survival/index.html
• 18 Drawing Survival Curves using 'ggplot2'. R package version 0.4.9 https://cran.r-project.org/web/packages/survminer/survminer.pdf
• 19 Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer; 2000
• 20 Seo GH, Cho YY, Chung JH. et al. Increased risk of leukemia after radioactive iodine therapy in patients with thyroid cancer: a nationwide, population-based study in Korea. Thyroid 2015; 25: 927-934
• 21 Orosco RK, Hussain T, Noel JE. et al. Radioactive iodine in differentiated thyroid cancer: a national database perspective. Endocr Relat Cancer 2019; 26: 795-802